While the industry obsesses over faster chips and bigger context windows, AlixPartners consultant Kevin Madura argues the real disruption ...
In vegetated environments, such as forests, exploratory robots play a vital role in navigating complex, cluttered ...
In an era where AI models can be as creative as they are deceptive, Vals AI founder Rayan Krishnan argues that a company's evaluation framework is ...
Recursive self-improvement” is the idea that artificial intelligence could learn to build and train itself, creating ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
AI agents are not yet creative enough to carry out genuinely innovative open-ended AI research, it seems. The AI industry’s boldest promise right now is that AI will soon improve itself, with almost ...
His love of PCs and their components was born out of trying to squeeze every ounce of performance out of the family computer. Tinkering with his own build at age 10 turned into building PCs for ...
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. The above button links to ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
View the basic RXRX option chain and compare options of Recursion Pharmaceuticals, Inc. on Yahoo Finance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results